Drug
JY231 clinical trials
- studies test it
- 12
- open now
- 12
- in phase 3
- 0
- first study started
- 2023
Keep track of what changes. Save the JY231 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
12 studies that test it; most in 2025 (9)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 9 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 1
- Phase 2
- 1
- No phase
- 10
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 9
He Huang (3) · 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China (3) · Tongji Hospital (2) · Shenzhen Genocury Biotech Co., Ltd. (2) · LiangZou (1) · Affiliated Hospital of Guangdong Medical University (1)
Studies
Open first, then newest update. How each study uses JY231 is read from its arms, and is right about nine times in ten.
Testing it · 12
- CAR-T Therapy for Refractory Autoimmune DiseasesRecruitingNot applicableLiangZouNCT07059169Written as JY231 (JY231 injection)
- JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingEarly Phase 1920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaNCT06514768Written as JY231
- JY231(JY231) Injection for the Treatment of R/R B-cell MalignanciesRecruitingNot applicable920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaNCT07065279Written as JY231 Injection
- JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ LeukemiaRecruitingNot applicableTongji HospitalNCT06689917Written as JY231 Injection
- JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ LeukemiaRecruitingNot applicableAffiliated Hospital of Guangdong Medical UniversityNCT06940960Written as JY231 Injection
- JY231 Injection for the Treatment of Relapsed/Refractory Neurologic Immune DisordersRecruitingNot applicableTongji HospitalNCT06797024Written as JY231 Injection
- JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ LeukemiaRecruitingNot applicableShenzhen Genocury Biotech Co., Ltd.NCT06890065Written as JY231 Injection
- JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell LeukemiaNot yet recruitingNot applicableHe HuangNCT06902025Written as JY231 Injection
- JY231(JY231) Injection for the Treatment of Refractory Autoimmune Diseases (ADs)Not yet recruitingNot applicableHe HuangNCT06887985Written as JY231 Injection
- JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell LymphomaNot yet recruitingNot applicableHe HuangNCT06879470Written as JY231 Injection
- JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ LeukemiaRecruitingNot applicableShenzhen Genocury Biotech Co., Ltd.NCT06678282Written as JY231 Injection
- JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE)RecruitingPhase 1/2920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaNCT06675422Written as JY231 injection